- DescriptionAnti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (SAD-S35) is isolated from a SARS-CoV-2 infected patient and is recombinantly produced from human 293 cells (HEK293). This antibody recognizes the SARS-CoV-2 Spike Protein RBD domain and inhibits the interaction between SARS-CoV-2 RBD and ACE2 with an IC50 of 1.47 μg/mL using SARS-CoV-2 Inhibitor Screening Kit (Cat. No. EP-105). Pseudovirus assay shows that this antibody has potent neutralizing activity against pseudovirus bearing SARS-CoV-2 Spike protein.
- IsotypeHuman IgG1/kappa
- SpecificityThis product is a specific neutralizing antibody against SARS-CoV-2 Spike Protein RBD domain and no cross-reactivity was detected against SARS-CoV Spike protein. The cross-reactivity with other coronaviruses has not been tested yet.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 . Normally trehalose is added as protectant before lyophilization.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 years under sterile conditions after reconstitution.
Serial dilutions of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat.No. SAD-S35) was detected by SARS-CoV-2 Inhibitor screening Kit (Cat.No. EP-105) with a half maximal inhibitory concentration (IC50) of 1.472 μg/mL (QC tested).
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H4) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) with a linear range of 0.2-1.95 ng/mL (QC tested).
Determination of Anti-SARS-CoV-2 Neutralizing Antibody titer in different concentrations of human serum.Neutralizing titer of Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 (Cat. No. SAD-S35) measured by Anti-SARS-CoV-2 neutralizing antibody titer serologic assay kit (Cat. No. TAS-K003) in different concentrations of human serum (CV < 30%)="" (routinely="" tested).="">
- BackgroundIt"s been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
AcroBiosystems是专注于生物药开发过程的蛋白技术和产品的全球化品牌，目前位于美国特拉华州的纽瓦克市，是一家专业研发、生产、销售蛋白相关分子生物学试剂的高科技公司。AcroBiosystems从成立之初至今一直致力于提供在药物研发过程中所需的高质量的靶点蛋白，满足市场对大批量、高批间*性的蛋白试剂的需求，产品和服务面向全球制药公司、生物技术公司及科研院所。产品包括免疫检查点蛋白、生物素标记蛋白、Fc受体蛋白、CAR-T靶点蛋白等，基于AviTagTM标记技术和化学标记技术的生物素标记蛋白系列被广泛应用于Biacore，AlphaLisa，MSD等平台。这些产品受到了学术界的*好评。
CD Feed X Supplement Plus, Liquid No.CF-1116
产品介绍
品牌：acrobiosystems
规格：500ml
产品描述：CD细胞的生长的补充液是化学定义的，能显著提高细胞密度和延长细胞活力，从而增加靶蛋白的表达，使用剂量为5-10%（V/V）。与CD 293 TGE培养基配合使用，BPM-BPfectin和293-Expression MAX-1可提高蛋白表达量。
产品特性：① 显著提高生产率
② 无动物源、无蛋白质、无血清和化学成分
储存条件：2℃-8℃，避光。
产品参数：
部分产品的详细列表：AcroBiosystems授权代理
货号 | 产品 | 规格 | 价格（美元） |
BAF-HF268 | FITC-Labeled Human BAFF / TNFSF13B / CD257 Protein, Fc Tag | 25ug | $290 |
BCA-HF254 | FITC-Labeled Human BCMA, Fc Tag | 25ug | $290 |
BCA-HF2H1 | FITC-Labeled Human BCMA, His Tag | 25ug | $290 |
![ACROBiosystems/Influenza A[A/swine/Jiangsu/J004/2018(H1N1)] Hemagglutinin (HA) Protein, His Tag/1mg/HEN](images/no_picture.gif)
暂无问答
本网站将在规定时间内给予删除等相关处理。
